Adaptimmune initiates radiation sub-study of ADP-A2M4 trial
Adaptimmune Therapeutics has initiated a radiation sub-study of its ADP-A2M4 trial in collaboration with the University of Texas MD Anderson Cancer Center in Houston, TX. Published data indicate that low-dose radiation has the potential to enhance T-cell responses in the context of solid tumors. The radiation sub-study is planned to enroll 10 patients across multiple solid tumor indications. Patients will receive low-dose radiation in up to 5 lesions prior to treatment with ADP-A2M4, at target doses of 1 to 10 billion SPEAR T-cells. The lymphodepletion regimen will be fludarabine for 4 days and cyclophosphamide for 3 days. Adaptimmune and the MD Anderson Cancer Center have a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.